Endovascular Treatment With Versus Without Intravenous rhTNK-tPA in Stroke — BRIDGE-TNK  

Stroke, Acute Clinical Trial

Official title: Intravenous rhTNK-tPA Bridging With Endovascular Treatment Versus Endovascular Treatment Alone For Stroke Patient With Large Vessel Occlusion: A Multicenter, Randomized Controlled Trial

Status Recruiting

Clinical Trial Summary

The purpose of this trial is to investigate whether intravenous rhTNK-tPA prior to endovascular treatment can improve 90-day functional outcome of stroke patients with large vessel occlusion who are thrombolysis-eligible within 4.5 hours of symptom onset.

Clinical Trial Description

The DEVT, SKIP and DIRECT-MT trials showed that endovascular treatment alone is not inferior to intravenous alteplase bridging with endovascular treatment in terms of achieving 90-day functional independence for stroke patients with large vessel occlusion. The EXTEND-IA TNK part 1 and part 2 demonstrated that intravenous thrombolysis with tenecteplase is superior to alteplase before endovascular treatment. However, it is unclear whether intravenous tenecteplase bridging with endovascular treatment is superior to endovascular treatment alone. The purpose of this trial is to investigate whether intravenous rhTNK-tPA bridging with endovascular treatment is better than endovascular treatment alone for stroke patients with large vessel occlusion who are thrombolysis-eligible within 4.5 hours of onset. ;

Related Conditions & MeSH terms

• Ischemic Stroke
• Stroke
• Stroke, Acute
• Stroke, Ischemic

• NCT number: NCT04733742
• Study type: Interventional
• Source: Xinqiao Hospital of Chongqing
• Contact: Zhongming Qiu, MD
• Phone: +8613236599269
• Email: qiuzhongmingdoctor@163.com
• Status: Recruiting
• Phase: Phase 2/Phase 3
• Start date: May 9, 2022
• Completion date: March 30, 2026